Annexin A1 (AnxA1), a 37 kDa protein modulated by the actions of glucocorticoids is one such molecule currently assessed as a potential target for therapy of not only IBDs, but of other inflammatory chronic diseases as well, playing roles on the inflammatory modulation of diseases such as asthma, type-2 diabetes, cystic fibrosis, rheumatoid arthritis, among others (Patel et al., 2012; Perretti and D’acquisto, 2009; Perucci et al., 2017; Sheikh and Solito, 2018). This evidence concerns the gene ANXA1 and cystic fibrosis.